Viatris (WBO:MYL) Other Stockholders Equity : €0 Mil (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Viatris Other Stockholders Equity?

Viatris's Other Stockholders Equity for the quarter that ended in Dec. 2023 was €0 Mil.

Viatris's quarterly Other Stockholders Equity increased from Jun. 2023 (€0 Mil) to Sep. 2023 (€0 Mil) but then declined from Sep. 2023 (€0 Mil) to Dec. 2023 (€0 Mil).

Viatris's annual Other Stockholders Equity increased from Dec. 2021 (€0 Mil) to Dec. 2022 (€0 Mil) but then declined from Dec. 2022 (€0 Mil) to Dec. 2023 (€0 Mil).

Viatris Other Stockholders Equity Historical Data

The historical data trend for Viatris's Other Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viatris Other Stockholders Equity Chart

Viatris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Stockholders Equity

Get a 7-Day Free Trial

Viatris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Other Stockholders Equity	Get a 7-Day Free Trial															-	-	-	-	-

Viatris Other Stockholders Equity Calculation

Other Stockholders Equity is instruments issued by the company that cannot be identified by other specific items in the Equity section. GuruFocus lists following items in "Total Stockholders Equity" section:
Common Stock
Preferred Stock
Retained Earnings
Accumulated other comprehensive income (loss)
Additional Paid-In Capital
Treasury Stock
Other Stockholders Equity

Viatris Other Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Viatris's Other Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Viatris (WBO:MYL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Viatris Inc (WBO:MYL) » Definitions » Other Stockholders Equity

Comparable Companies

Traded in Other Exchanges

VTRS:USA MYL:Mexico 1VTRS:Italy 0A5V:UK VIA:Germany

Address

1000 Mylan Boulevard, Canonsburg, PA, USA, 15317

Website

https://www.viatris.com

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Viatris (WBO:MYL) Headlines

No Headlines